Advertisement

Françoise Mornex, MD, PhD, Honored With IASLC Distinguished Award


Advertisement
Get Permission

Françoise Mornex, MD, PhD

Françoise Mornex, MD, PhD

Françoise Mornex, MD, PhD, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. 

Dr. Mornex is Professor of Oncology at the University Claude Bernard in Lyon, France, and Past Chair of the Radiation Oncology Department at the Centre Hospitalier Lyon Sud, where she practices radiotherapy and medical oncology. Her work is focused in the field of combined chemoradiation, where she has assumed a leadership role in the development of multimodal treatment for lung and digestive tract tumors. Her current research interests include the development of new chemoradiation treatments and the design of phase I, II, and III randomized trials, including the recent implementation of immunotherapy.

“Professor Françoise Mornex has served the IASLC in a range of roles over many years. She has inspired many younger colleagues to join the field and to join the IASLC,” said Fred R. Hirsch, MD, PhD, Chief Executive Officer of the IASLC. “We feel honored to acknowledge Professor Mornex’s contribution to the IASLC with this Distinguished Award.”

Professional Experience

Professor Mornex joined the IASLC in 1987 and served on its Board of Directors from 2013 to 2017. She has organized many national and international meetings, including multiple IASLC lung cancer workshops. She was Co-President of the highly successful first and second European IASLC-ESMO lung cancer conferences in Geneva in 2008 and 2010. She is the general secretary and a member of the French Radiation Oncology Society, as well as a member of the American Society for Therapeutic Radiology and Oncology and the Intergroupe Françophone de Cancérologie Thoracique, among others. 

Professor Mornex graduated from the University Claude Bernard with a PhD and a MD and a Habilitation to Direct Research. She also completed a 2-year fellowship in radiation oncology and research at the National Cancer Institute in Bethesda, Maryland. ■


Advertisement

Advertisement



Advertisement